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1. Introduction
An antibacterial is a compound or substance that kills or slows down the growth of bacteria.
We usually associate the beginning of the modern antibacterial era with the names of Paul
Ehrlich and Alexander Fleming. Infectious diseases are the leading causes of human mor‐
bidity and mortality for most of human existence. Antibacterials are probably one of the
most successful forms of chemotherapy in the history of medicine. They save countless lives
and make enormous contribution to the control of infectious diseases since the beginning of
antibacterial era. Perhaps most of us born since the Second World War don’t know how
much enthusiasm, dedication, and hardship have been put in antibacterial drug discovery,
and take the success of antibacterial agents too much for granted. Therefore, let’s first look
back what the human did to combat the infections before antibacterial era and how the out‐
standing scientists discovered so many efficient antibacterial agents used clinically today
and led us enter the antibacterial era.
2. The history of antibacterial discovery
2.1. Pre-antibiotic era
Before the early 20th century, treatments for infections were based primarily on medicinal
folklore. Mixtures with antimicrobial properties that were used in treatments of infections
were described over 2000 years ago [1]. Even the prehistoric peoples used a number of
plants in wound treatment and it seems possible that many plants have the properties of an‐
timicrobial effects [2; 3]. Tetracyclines can be incorporated into the hydroxyapatite mineral
portion of bones as well as tooth enamel; once people take it, permanent markers of meta‐
bolically active areas will be left. Thus it is much conveniently to trace the exposure of these
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antibacterials in ancient populations. It was found than the bone sample from Sudanese Nu‐
bian (A.D. 350 to 550) was labeled by the antibiotic tetracycline and their dietary regime con‐
tained tetracycline-containing materials by X-group cemetery and other advanced
technologies [4; 5]. Moreover, another study showed that, bones from the Dakhleh Oasis,
Egypt, in a late Roman period, exhibit discrete fluorochromelabelling, exactly like the teeth
from patients treated with tetracycline [6]. A large number of customs and anecdotes can al‐
so reveal the occurrences of other antibacterials. One popular anecdote is about the antibiot‐
ic-like properties of red soil from the Hashemite Kingdom of Jordan. Interestingly, red soil
was used for treating skin infections and diaper rash in the past and is still used in some
communities today as an inexpensive alternative to antibiotics [7]. In fact, recently, many
pharmaceutical antibiotics, such as streptomycin, actinomycin, erythromycin, vancomycin,
nystatin and amphotericin, were produced from the soil actinomycetes [8].
The traditional Chinese medicine is the summary of experience about Chinese medical treat‐
ment over millennia and may contain a lot of unknown antibiotics [9]. Many traditional Chi‐
nese medicines were tested and found effective against four common oral bacteria [10].
Discovery of active components in the ancient herbs could enrich the arsenal of antimicrobi‐
als used by the mainstream medicine.
2.2. Foundation of the antibiotic era
Bacteria were first identified in the 1670s by van Leeuwenhoek, following his invention of
the microscope. The relationship between bacteria and diseases gradually set up in the nine‐
teenth century. Since then, researchers started to try and find effective antibacterial agents.
Paul  Ehrlich is  the  father  of  chemotherapy and was honored with the Nobel  prize  due
to the molecular side-chain theory of immunity. His concept of “magic bullet” is that the
chemicals selectively target only disease-causing microbes but not the host cells. In 1906,
Ehrlich, together with Bertheim, developed hundreds of derivatives of Atoxyl, and final‐
ly discovered compound 606,  a  gold powder [9;  11].  In 1909,  he found that  Compound
606  could  cure  syphilis-infected  rabbits  in  experiments;  it  could  also  improve  terminal
patients  with  dementia  and  cured  early  stage  patients  with  infected  sores  [11].  It  was
publicly released as salvarsan in 1910. Despite the adverse side effects, salvarsan and it’s
derivative neosalvarsan kept the status of  the most frequently prescribed drug until  the
introduction of  penicillin in the 1940s [12].  Amazingly,  the chemical  structure of  salvar‐
san hadn’t been known until 2005 [13].
The systematic screening approach introduced by Paul Ehrlich became the cornerstone of
drug search strategies in the pharmaceutical industry. Sulfonamidochrysoidine (also named
prontosil), the first commercially available antibiotic, was first synthesized by Bayer chem‐
ists Josef Klarer and Fritz Mietzsch in 1930s by this approach. Then Gerhard Domagk found
its effect against Streptococcus pyogenes in mice [14]. Four years later he received the Noble
Prize. Eventually prontosil was recognized as a precursor for a new class of antibacterial
agents— sulfonamides.
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The effect of mould on bacterial colonies hadn’t been investigated until 19th century, al‐
though the antibacterial properties of mold had been known since ancient times. In 1921,
Alexander Fleming observed some substances called lyzosomes which could dissolve bacte‐
ria. In 1928, he discovered that a specific mould species inhibited the development of Staph‐
ylococcus bacteria. The species was known as Pencilliumnotatum and the filtrate was called
penicillin [15]. In 1940, Howard Florey and Ernst Chain worked out how to purify penicillin
for clinical testing [16]. All the three researchers were awarded the Nobel Prize in 1945, and
since then the era of antibiotics had been initiated. Penicillin became the top therapeutic
molecule because of its widespread use and the magnitude of the therapeutic outcomes, and
also because of the technologies developed for production of penicillin which became the
basis for production of all subsequent antibiotics and other bioproducts in use today [17].
3. Classification
Antibacterials are commonly classified based on their mechanism of action or spectrum of
activity. The main classes of antibacterial drugs target only four classical bacterial functions:
bacterial-cell-wall biosynthesis (e.g., penicillin and vancomycin); bacterial protein biosynthe‐
sis (e.g., aminoglycoside and macrolide); DNA and RNA replication (e.g., ciprofloxacin and
rifampin); and folate coenzyme biosynthesis (e.g., sulfamethoxazole) [18]. Antibacterials that
target the cell wall or cell membrane or essential bacterial enzymes are more likely to be bac‐
tericidal; but generally the bacteriostatic is the antibacterial drugs that inhibits protein syn‐
thesis [19]. Another way to distinguish the antibiotics is based on their target specificity. The
broad-spectrum antibiotic affects a wide range of disease-causing bacteria, including both
Gram-positive and Gram-negative bacteria, in contrast to a narrow-spectrum antibiotic,
which acts against specific families of bacteria. For example, ampicillin is a widely used
broad-spectrum antibiotic.
4. Antibacterial resistance and its mechanisms
Bacterial resistance to antibacterial drugs increasingly becomes a major health and economic
problem, eroding the discovery of antibiotics and their application to clinical medicine. As
early as 1946, Alexander Fleming predicted that “There is probably no chemotherapeutic
drug to which in suitable circumstances the bacteria cannot react by in some way acquiring
‘fastness’ (resistance).” Today it is really the truth. Resistance to the antibiotics will emerge
only a few years after it is introduced to clinic use [20]. Bacterial resistance is positively cor‐
related with the use of antibacterial agents in clinical practice [21; 22]. Because any use of
antibiotics can increase selective pressure in a population of bacteria, allowing survival of
the resistant bacteria and death of the susceptible ones. We can find that pathogenic bacteria
are resistant to practically all available antibacterial drugs. And many strains, which are in‐
formally called superbugs, are even resistant to several different antibiotics. Multidrug re‐
sistance has been found in Pseudomonas aeruginosa (P. aeruginosa),
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Acinetobacterbaumannii (A. baumannii), E. coli, and Klebsiellapneumoniae (K. pneumo‐
niae), producing extended-spectrum β-lactamases (ESBL), vancomycin-resistant enterococci
Enterococcus faecium (E. faecium) (VRE), MRSA, vancomycin-resistant S. aureus VRSA, ex‐
tensively drug-resistant (XDR) Mycobacterium tuberculosis (M. tuberculosis), Salmonella
enterica (S. enterica) serovar Typhimurium, Shigelladysenteriae (S. dysenteriae), Haemophi‐
lusinfluenzae (H. influenzae), Stenotrophomonas, and Burkholderia [23; 24].
Great amount of antibiotic is used in nonhuman niches, leading to the spread of resistant
bacteria too. Antibiotics have been used for improving the production of livestock and poul‐
try for more than 50 years [25]. The Institute of Food Technologists (IFT), once convened a
panel of internationally renowned experts to address the concern that, the emergence of an‐
timicrobial resistance may result from abuse in food production, manufacturing, and else‐
where [26].
Over the past several years, people struggled to search for the mechanisms of resistance.
Therefore today there is a large pool of information about how drug resistances come out.
Biochemical and genetic aspects of antibiotic resistance mechanisms are shown in Fig. 1.
Figure 1. Kinds of antibiotic resistance mechanisms [85].
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4.1. Genetics of antibiotic resistance
Resistance can be an intrinsic property of the bacteria themselves or it can be acquired.
There are two main ways of acquiring antibiotic resistance: i) chromosomal mutations and
ii) horizontal gene transfer. But the question is where the horizontal gene comes from? Some
of these genes have an environmental origin and began their evolution before the antibiotic
era; most likely, the primary genes originated and diversified within the environmental bac‐
terial communities, then mobilized and penetrated into pathogens. [27; 28]
4.1.1. Mutations
4.1.1.1. Spontaneous mutations
These mutations occur randomly as replication errors or an incorrect repair of a damaged
DNA in actively dividing cells, presenting an important mode of generating antibiotic resist‐
ance. They are also called the growth dependent mutations. Quinolone resistance in Escheri‐
chia coli resulted from the mutations in at least seven positions in the gyrA gene or three
positions in the parC gene [29]. There are a large number of biochemical mechanisms of an‐
tibiotic resistance related to Spontaneous Mutations. For instance, Mutations in mexR can
cause derepression of the mexAB-oprM multidrug efflux operon, causing a multidrug resist‐
ance phenotype in Pseudomonas aeruginosa [30].
4.1.1.2. Hypermutators
During a prolonged non-lethal antibiotic selective pressure a small bacterial population en‐
ters a transient state of a high mutation rate which is called hypermutable state. Hypermuta‐
tors are found in many bacteria species such as E. coli, S. enterica, Neisseria meningitides
(N. meningitides),H. influenzae, S. aureus, Helicobacter pylori (H. pylori), Streptococcus
pneumoniae (S. pneumoniae),and P. aeruginosa [85]. Various studies suggested that hyper‐
mutations play an important role in acquisition of antibiotic resistance in pathogens [31; 32;
33].
4.1.1.3. Adaptive mutagenesis
Adaptive mutations arise in non-dividing or slowly dividing cells during the presence of a
non-lethal selective pressure that favours them. A great number of antibiotic resistant mu‐
tants may come from this mutation process under bacterial natural conditions [85].
4.1.1.4. Horizontal gene transfer
Horizontal transfer of genetic material between bacteria is the most commonly used way to
spread antibiotic resistance. In general, this exchange is accomplished mainly through the
processes of transduction (via bacteriophages), conjugation (via plasmids and conjugative
transposons), and transformation (via incorporation into the chromosome of chromosomal
DNA, plasmids, and other DNAs) [34]. This type of genetic transfer not only occurred be‐
tween closely related bacteria but can also occur between phylogenetically distant bacterial
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genera, in particular between gram-positive and gram-negative bacteria [35]. Plasmid-en‐
coded antibiotic resistance encompasses most classes of antibiotics in practice, such as ami‐
noglycosides, cephalosporins and fluoroquinolones [36]. Transposons spread quicker than
genes in chromosomes and are transferred by conjugation, transformation, or transduction
[23; 24]. Integrons acquire and exchange exogenous DNA, known as gene cassettes, by a
site-specific recombination mechanism. They can integrate stably into other DNAs where
they deliver multiple antibacterial resistant genes in a single exchange. Resistance gene cas‐
settes encoding the metallo-β- lactamases IMP and VIM confer resistance to the potent car‐
bapenem β-lactams imipenem and meropenem [36].
4.1.2. Biochemistry of antibiotic resistance
As so many scientists have been struggling to study the biochemical mechanisms of antibi‐
otic resistance, nowadays there is a large pool of related valuable information left. Biochemi‐
cal mechanisms may be varied among different bacterial species, but can be mainly
classified into four categories (Fig. 2). In fact, each of these four categories also contains an
amazing diversity of resistance mechanisms. Sometimes a single bacterial strain may pos‐
sess several types of resistance mechanisms. Each of the four main categories will be dis‐
cussed respectively below.
4.1.2.1. Antibiotic inactivation
Biochemical strategies include enzymatic modification and redox mechanisms (which is less
important and will not be elaborated in this paper). Enzymes can be divided into two gener‐
al classes: those such as β-lactamases that degrade antibiotics and others that perform chem‐
ical transformations. The antibiotic β-lactam has a four-atom ring known as a beta-lactamin.
The β-lactamase enzyme breaks that ring open, destroying the antibacterial properties of the
drugs. β-lactamase consists of enzymes with a serine residue at the active site, and metal‐
loenzymes with zinc ion as a cofactor and with a separate heritage [37]. β-lactamase en‐
zymes are the most common and important weapons for Gram-negative bacteria to resist
the antibiotics β-lactam [38]. The group transfer approaches are the most diverse and in‐
clude the modification by acyltransfer, phosphorylation, glycosylation, nucleotidylation, ri‐
bosylation, and thiol transfer. They can inactivate antibiotics (aminoglycosides,
chloramphenicol, streptogramin, macrolides or rifampicin) by chemical substitution. These
modifications reduce the affinity of antibiotics to a target [85]. For example, enzymatic mod‐
ification is the most prevalent mechanism to destroy aminoglycosides in clinic. Aminoglyco‐
side modifying enzymes can be divided into three classes: acetyltransferases,
nucleotidyltranferases, and phosphotransferases; they mainly catalyze the modification at –
OH or –NH2 groups of the 2-deoxystreptamine nucleus or the sugar moieties [39]. There are
a large number of genes in the chromosomes and other mobile genetic elements coding for
these enzymes which let the bacteria resist to more new antibiotics as well as horizontally
spread their resistance among bacteria more easily. As a consequence, almost all pathogens
are resistant to aminoglycosides through modifying enzymes [39].
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4.1.2.2. Target modification
Another important resistance mechanism is the modification of antibiotic targets which
makes the antibiotic unable to bind the targets properly. β-lactams target the bacterial en‐
zymes of cell wall biosynthesis (the so-called penicillin-binding proteins, PBPs). Alterations
in PBPs can reduce affinity for β-lactams, possibly causing β-lactam resistance in many bac‐
teria strains, such as H. influenzae, N. gonorrhoeae, N. meningitidis, anaerobes, S. dysenter‐
iae [40]. For instance, the mecA resistance gene which encodes PBP2a, a new penicillin
binding protein with decreased affinity for oxacillin and most other β-lactam drugs, induces
resistance to methicillin and oxacillin in S. aureus [41]. The resistance to antibiotics that in‐
terfere with protein synthesis or transcription is achieved by modification of the specific tar‐
get. rRNAmethylases encoded by a number of genes modificate the 16S rRNA molecule at
specific positions critical for aminoglycosides binding [42]. Modification in the 23S rRNA
component of the 50S ribosomal subunit also leads to resistance to the macrolide, lincosa‐
mide and streptogramin B group of antibiotics in many pathogen strains [43; 44]. Mutations
of topoisomerase IV and gyrase genes can sufficiently alter affinity of fluoroquinolones to
these enzymes [45].
4.1.2.3. Efflux pumps and outer membrane (OM) permeability
Efflux pumps Membrane proteins that export antibiotics from the cell and maintain their low
intracellular concentrations are called efflux pumps. Drug efflux pumps play a key role in
drug resistance not just because they can produce multidrug resistance but also because
they can elevate level of other resistance mechanisms [46; 47]. Bacterial drug efflux trans‐
porters are currently classified into five families: the ATP-binding cassette (ABC) superfami‐
ly, the major facilitator superfamily (MFS), the multidrug and toxic compound extrusion
(MATE) family, the small multidrug resistance (SMR) family, and the resistance-nodulation‐
division (RND) superfamily [47]. Efflux transporters can be further classified into single or
multicomponent pumps. Tetracycline and macrolide transporters are single component ef‐
flux systems that have narrow substrate profiles, while the RND family members have
broader substrates and can pump out multiple structurally unrelated compounds [24; 46].
Efflux pumps exist in both Gram-positive and Gram-negative bacteria [48; 49]. MexAB-
OprM efflux pumps in Pseudomonas aeruginosa, which belong to RND family, result in
higher inhibitory concentration of a large number of antibiotics, such as penicillins, broad‐
spectrumcephalosporins, chloramphenicol, fluoroquinolones, macrolides, novobiocin, sulfo‐
namides, tetracycline and trimethoprim, dyes and detergents [50; 51].
OM permeability The OM is an asymmetric bilayer: the phospholipid form the inner leaflet
and the lipopolysaccharides (LPS) form the outer leaflet. OM of Gram-negative bacteria pro‐
vides a formidable barrier that must be overcome by drugs. Drug molecules pass the OM by
diffusion through porins or the bilayer, or by self-promoted uptake [85]. Small hydrophilic
drugs (e.g., β-lactams), enter to the intracellular through the pore-forming porins, while
macrolides and other hydrophobic drugs diffuse during their entry [52]. Some resistant clin‐
ical strains of Neisseria meningitidis, K. pneumoniae and Enterobacteraerogenes exhibit a
noticeable porin variability resulting in decrease of antibacterial uptake [53]. Reduction of
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LPS in the outer membrane of Polymyxin-resistant P. aeruginosa strains associates with re‐
sistance development [54].
4.1.2.4. Target bypass
This kind of resistance mechanisms is somewhat specific.  Bacteria produce two kinds of
targets: one is sensitive to antibiotics and the alternative one (usually an enzyme) that is
resistant  to  inhibition  of  antibiotic.  In  ampicillin-resistant  mutant  Enterococcus  faecium
selected  in  vitro,  bypass  of  the  DD-transpeptidases  by  a  novel  class  of  peptidoglycan
polymerases,  the  LD-transpeptidases,  conveyed  resistance  to  all  β-lactams,  except  the
carbapenems [55; 56].
5. What should we do?
5.1. Extending the lifespan of existing antibacterials
Although the emergency of antibiotic resistance seems inevitable, measures must be taken to
prevent or at least delay this process. As mentioned above, many factors contribute to resist‐
ance, so we should adopt a complex approach. The most important way is to strictly control
antibiotic misuse and overuse. Interestingly, the EU has implemented a comprehensive ban
on the use of all antibiotics for growth promotion since 2006 [25]. And other developed
countries also implement similar measures, but in many developing nations antibiotic use is
relatively uncontrolled. As hospital-acquired infection is a major cause for antibiotic-resist‐
ance, strict antibiotic stewardship and policies should be adopted in the hospitals. For exam‐
ple, we can make some antibiotic policies to optimize the selection, dosing, route of
administration, duration of the drug prescribed by the doctor, and limit the unintended con‐
sequences of antibiotic utilization [57].
5.2. New antibacterial drug discovery
As serious infectious diseases and multidrug resistance are emerging repeatedly, new anti‐
biotics are needed badly to combat these bacterial pathogens, but the progress of discovery
seems relatively slow. Most chemical scaffolds of antibiotics used now were just introduced
between the mid-1930s and the early 1960s (fig 2). There are many reasons for this. The first
is scientific. We have discovered the easy-to-find antibiotics. Now we have to work harder
and think more cleverly to find new drugs. Another reason is commercial. Antibiotics are
used much less than other drugs and the new antibiotic are just used to treat serious bacteri‐
al infections at most of the time. So antibiotics have a poor return on investment. In 2008
only five major pharmaceutical companies still kept their Enthusiasm in antibacterial dis‐
covery. It is most important to delink research and development costs from drug pricing
and the return from investment on antibacterial discovery [58]. If the government could es‐
tablish some subsidies and financial assistance schemes to compensate the cost, more drug
companies will be attracted to this area.
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Figure 2. Innovation gap between 1962 and 2000 [59].
Despite the current grim situation in management of resistant bacteria, some new drugs
have recently been approved by the FDA or are in late stages of the pipeline (Table 1, 2) [60].
The new drugs belong to the following classes of compounds: oxazolidinones, glycopepti‐
des, ketolides, lycylcyclines, carbapenems and fluoroquinolones.
CLASS OF
COMPOUND
PHASE OF
DEVELO-
PMENT
ANALOGS MECHANISM OFACTION
RESISTANCE
MECHANISM
DRUG
COMPANY
Oxazolidinones FDA Approved2000
Linezolid,
Radezolid,
Torezolid, RWJ-
416457
Inhibits protein
translation
(initiation/
elongation)
rRNA mutations
Pfizer, Rib-X,
Trius Therapeutics,
Johnson & Johnson
Glycopeptides Phase III
Oritavancin,
Dalbavancin,
Telavancin
Inhibit
peptidoglycan
biosysnthesis/
transglycosylation
unidentified
Targanta/The
Medicines Co.,
Pfizer,
Theravance
Ketolides Phase III Cethromycin Inhibits proteinsynthesis
rRNA
dimethylation,
ribosomal protein
mutations
Advanced Life
Sciences
Glycylcyclines FDA Approved2005
Tigecycline,
PTK0796
Inhibits protein
synthesis Efflux pumps
Wyeth, Paratek
Pharmaceuticals
Carbapenems FDA Approved2007
Doripenem,
Razupenem
Inhibits
peptidoglycan
biosynthesis
Carbapenemases,
Efflux pumps,
Porin mutations
Johnson &
Johnson, Protez
Pharmaceuticals
Streptogramins Phase II NXL103/XRP2868 Inhibits proteintranslation unidentified Novexel
Fluoroquinolones Preclinical JNJ-Q2,finafloxacin
Inhibit type II
topoisomerase
gyrA, parC
mutations
Johnson &
Johnson,
MerLion
Pharmaceuticals
Table 1. New antibiotics of existing scaffolds
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DRUG NAME TARGET/MECHANISM OF ACTION
SPECTRUM OF
ACTIVITY
PHASE OF
DEVELO-PMENT
DRUG COMPANY OR
INNOVATOR
Ceftobiprole Tight binding toPBP2a
Gram-positive,
Gram-negative Phase III Johnson & Johnson
Ceftaroline Tight binding to PBP2a Gram-positive,Gram-negative Phase III Forrest Laboratories
Iclaprim Increased affinityto bacterial DHFR
Gram-positive,
Gram-negative Phase III Arpida
Sulopenem Binding to PBPs Gram-negative preclinical Pfizer
BAL30376
Monobactam/β-
lactamase inhibitor
combination
Multi-drug
resistant
Gram-negative
preclinical Basilea
Rx100472 MethionyltRNAsynthetase inhibitor Gram-positive preclinical Trius Therapeutics
PC190723 Cell divisionprotein FtsZ S. aureus preclinical Prolysis
MUT7307
Enoyl-ACP FabI
reductase (fatty acid
biosynthesis)
Gram-positive,
Gram-negative preclinical Mutabilis
Nitazoxanide
Inhibits vitamin cofactor of
pyruvate:ferredoxin
oxidoreductase (PFOR)
C. difficile Phase II RomarkLaboratories
Fidaxomicin
(OPT-80) Inhibits RNA synthesis C. difficile Phase II
Optimer
Pharmaceuticals
LED209 Quorum sensing S. typhimuriumF. tularensis preclinical
University of Texas
South Western
Medical Center,Dallas
BPH652 Virulence factor(antioxidant) MRSA preclinical
University of
Illinois, Chicago
Omiganan
Antimicrobial peptide;
Depolarizes cytoplasmic
membrane of bacteria
Gram-positive,
fungi Phase III
MIGENIX, Cadence
pharmaceuticals
TMC207 ATP synthaseinhibition M. tuberculosis Phase II
Johnson & Johnson,
Tibotec
CBR2092 Dual pharmacophore Gram-positive Phase I Cumbre
Amikacin Novel drug delivery:inhaled nanoliposomes
P. aeruginosa
biofilm Phase II Transave Inc.
Table 2. New antibiotics in development
5.2.1. Tailoring existing scaffolds
It seems that there are many ways to search for new antibacterials, but the key question is:
how to search for new antibacterial drugs and where to look for them? The most convenient
method is to modify the existing scaffolds to generate their derivates. All antibiotics ap‐
proved between the early 1960s and 2000 were synthetic derivatives of the old scaffolds ex‐
cept carbapenems. Chemical modifications of old scaffolds may lead to improved
bactericidal activities, better resistance profiles, safety, tolerability or superior pharmacoki‐
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netic/pharmacodynamic properties. There are four generations of β-Lactam antibiotics, all of
which contains a β-lactam nucleus in their molecular structures. The second generation (e.g.,
cephalexin and cefaclor) and third generation (e.g., cefotaxime, ceftazidime) are not sensitive
to plasmid-mediated broad-spectrum β-lactamases and have less allergic reactions, com‐
pared with the first generation (penicillins) [61]. The fourth-generation cephalosporins pene‐
trate through the outer membrane of Gram-negative bacteria more easily and have low
affinity for clinically important β-lactamases, so they have the advantage of killing many
Gram-negative pathogens resistant to most third-generation [86]. Tigecycline is one of gly‐
cylcycline antibiotics derived from tetracycline and received approval from the US Food and
Drug Administration for the treatment of skin, soft-tissue, and intra abdominal infections in
2005. Tigecycline can overcome the active efflux of drug from inside the bacterial cell and
protection of ribosomes, which are two determinants of tetracycline resistance [62; 63]. But
this approach is only a good short-term strategy to find new drugs, and but the benefit of
these modified drugs will be offset quickly by the resistance to acquired through the hori‐
zontal acquisition or molecular evolution [9], which indicates that it is much more attractive
to find novel chemical scaffolds.
5.2.2. Novel scaffolds
5.2.2.1. Explore new places
More than two-thirds of clinically used antibiotics come from natural products or their semi
synthetic derivatives and most of them came out from soil actinomycetes. But recently re‐
searchers have shifted to underexplored ecological niches and bacterial species and found
some new scaffolds. Compared to the terrestrial environment, the ocean remains an under-
explored habitat with unparalleled biodiversity, leaving it the most promising place to yield
new antibacterial metabolites. New antibacterial agents with novelty and/or complexity in
chemical structure derived from marine bacteria have been elaborated clearly [64; 65]. Myx‐
obacteria, a untapped bacterial strain, can produce many useful natural products which
have great potential to develop into antibacterial drug [66].
5.2.2.2. The genomics
By the mid-1990s, pharmaceutical companies have little enthusiasm for making improve‐
ment to the existing antibacterials. Hundreds of bacterial genomes have been completely de‐
ciphered since 1995, among which are many important human pathogens, attracting large
pharmaceutical companies back into antibacterial discovery [67]. Genomics influence vari‐
ous aspects of the antibiotic development, including new drug target identification, under‐
standing the mechanism of antibiotic action, drug safety and efficacy assessment, bacterial
resistance development, and so on [68]. Ecopia Biosciences was very skilled in using ge‐
nome-scanning approach and discovered the new antibiotic scaffold ECO-0501 which is
highly effective against a series of Gram-positive pathogens [59; 69]. GlaxoSmithKline also
used a genomics-derived, target-based approach to screen for new drugs. They examined
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more than 300 genes and employed 70 high-throughput screening campaigns over a period
of 7 years, but unfortunately did not create a clinical used antibacterial [70].
5.2.2.3. New targets
It must be admitted that target-based genomic approach has not yielded satisfactory results,
nevertheless, retooled target-based strategies can still play an important role in discovery
process. Most antibiotic targets are limited to peptidoglycan synthesis, ribosomal protein
synthesis, folate synthesis, and nucleic acid synthesis and topoisomerization. In the future
we could continue to discover new antibiotics for these old targets through improvement of
the existing scaffolds or even finding new scaffolds. For instance, Lipid II is a membrane-
anchored cell-wall precursor that is essential for bacterial cell-wall biosynthesis; it is not on‐
ly classical target for several old antibacterial classes, but is also targeted by the new
antibiotics, such as lantibiotics, mannopeptimycins and ramoplanin [71]. Grouping targets
by a common inhibitor scaffold rather than by function may lead to new targets; and as
mentioned above, insights from outside the antibiotic arena are also important [59].
5.2.2.4. Forward is back
Compared with the fruitless target-based genomic approach, traditional whole-cell assays
are more effective in antibiotic discovery. Just because it is not necessary to worry about cell
permeability of a novel scaffold in the development process if whole-cell assays are used. As
most of the existing libraries have already been used to screen for antibacterial drugs, libra‐
ries with new chemical diversity are extremely important in this approach. Sometimes, look
for libraries that don’t belong to antibacterial development areas may be useful. In fact, most
pharmaceutical companies of other therapeutic areas have invested considerable resources
in synthesizing small molecule libraries [59]. Candidates with a strong hit in a whole-cell an‐
tibacterial assay should be tested in the right animal model early in development, because In
vitro experiment results are not always reliable. For example, Antimicrobial drug target type
II fatty acid synthesis (FASII) is reported to be essential for their efficacy against infections
caused by multiresistant Gram-positive bacteria. But another study showed that Streptococ‐
cus agalactiae and S. aureus could take up sufficient unsaturated fatty acids from human se‐
rum to obviate the essentiality of FAS II enzymes in vivo [72].
5.2.2.5. Focus on spectrum
Antibacterial spectrum is a major consideration when selecting a target for lead optimiza‐
tion. Permeability and target distribution determine the pectrum [73]. That is to say, the
drug candidates should possess two properties at the same time: one is penetrating the cell
and evading efflux pump systems, another is retaining potent activity at the molecular tar‐
gets. However, since almost all targets of the antibacterials in clinical use are present in all
bacteria, the antibacterial drug spectra are determined largely by the ability of permeability.
Therefore, some compounds are just Gram-positive organism-selective and have no effect
against Gram-negative pathogens which have a second membrane acting as a permeability
barrier [74; 75]. Efflux pump inhibitors (EPIs) have been explored for broadening the anti‐
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bacterial spectrum and overcoming bacterial resistance. Although no clinically useful drugs
have come out, extensive efforts have been made to test the effectiveness of EPIs across a
range of in vitro and in vivo assays, especially the compound MC-207,110 [76].
‘Broader is better’ is the rule of antibacterial activity spectrum. But developing the agents
with a narrower spectrum may be helpful in treating some special antibiotic resistant patho‐
gens or the non-multiplying bacteria. One human squalene synthase inhibitor blocked
staphyloxanthin biosynthesis in vitro, resulting in colorless bacteria which became more
sensitive to killing by human blood and innate immune clearance [77]. Rifampicin is a
standard antibiotic used for clearance of non-multiplying tuberculosis. Monoclonal antibod‐
ies (Mabs) have also become potential agents for narrow-spectrum antibacterial therapy. In
clinical experiment C. difficile Mab combination MDX-066 and MDX-1388, which targets
and neutralizes two main C. difficile toxins, can reduce the recurrence of C. difficile infec‐
tion [78; 79]. A microbiologic diagnosis should be made before using these kinds of antibiot‐
ics for therapy. Such genus-selective agents may have the benefit of leaving more of the
endogenous microfloraun unattacked compared with conventional antibiotics.
5.2.2.6. Other new methods
Bacteriophages
Bacteriophages and their fragments could kill the bacteria. They have been developed as an‐
tibacterials in humans, poultry and cattle industries, aquaculture and sewage treatment.
This approach has novel mechanism of action that is completely different from current anti‐
microbials, but the problems are that quality control and standardization are difficult. Phage
lysins, which are produced late in the viral infection cycle, can bind to cell wall peptidogly‐
can and rapidly induce Gram-positive bacteria lysis [80]. The sequencing of phages genomes
may identify more proteins suitable for novel antibacterials [81; 82].
Other methods to find new drugs could be modulating immunity, developing monoclonal
antibody for specific bacteria, designing antibacterial peptides (including antimicrobial pep‐
tides and compounds from animals and plants, the natural lipopeptides of bacteria and Fun‐
gi [83; 84]), and so on.
6. Conclusion and future issues
While the antibacterial resistance, especially multi-drug resistance continues to rise, what
we should do is to investigate the potential mechanisms of drug resistance in bacteria and
discover more effective antibacterials to deal with the terrible problems. Luckily there are
several promising antibacterial drugs with novel mechanisms of action are in development
and new types of targets have emerged. Also we need to be more precise in targeting the
pathogens and limit the misuse of antimicrobials and other practices that accelerate the
emergence of novel resistance mechanisms. The government must offer robust financial in‐
centives for antibacterial R&D, and build a sustainable model for developing and using anti‐
bacterials.
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